Mar 18 |
Eyenovia GAAP EPS of -$0.18 misses by $0.01, revenue of $2.58M beats by $2.46M
|
Mar 18 |
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
|
Mar 18 |
Earnings Scheduled For March 18, 2024
|
Mar 17 |
Eyenovia Q4 2023 Earnings Preview
|
Mar 13 |
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
|
Mar 11 |
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
|
Mar 5 |
Eyenovia falls despite FDA nod for pain therapy
|
Mar 5 |
Beyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa's Steroid For Post-Eye Surgery Pain, Inflammation
|
Mar 5 |
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
|
Mar 4 |
UPDATE 2-US FDA approves Eyenovia's eye drug, Formosa Pharma says
|